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Abstract Epidermal growth factor receptor gene (EGFR)
alteration is a common feature in most of glioblastoma
multiforme (GBM). Robust response of anti-EGFR treat-
ments has been mostly associated with the EGFR deletion
mutant variant III (EGFRvIII) and expression of PTEN. We
have performed a prospective trial in order to confirm the
efficacy of erlotinib treatment in patients with relapsed
GBM who expressed EGFRvIII and PTEN. All patients
included in the trial were required to be PTEN (???),
EGFR (???) and EGFRvIII (???) positives by immu-
nohistochemistry. This new phase II trial enrolled 40
patients and was design to be stopped in case of fewer than
two responses in the first 13 patients. Patient eligibility
included histopathology criteria, radiological progression,
more than 18 years old, Karnofsky performed status,
KPS [ 50, and adequate bone marrow and organ function.
There was no limit to the number of prior treatments for
relapses. No enzyme-inducing antiepileptic drugs were
allowed. The primary endpoints were response and pro-
gression-free survival at 6 months (PFS6). Thirteen patients
(6 men, 7 women) with recurrent GBM received erlotinib
150 mg/day. Median age was 53 years, median KPS was 80,
and median prior treatments for relapses were 2. There was
one partial response and three stable diseases (one at
18 months). PFS at 6 months was 20 %. Dose reduction for
toxicity was not needed in any patient. Dermatitis was the
main treatment-related toxicity, grade 1 in 8 patients and
grade 2 in 5 patients. No grade 3 toxicity was observed.
Median survival was 7 months (95 % IC 1.41–4.7). As
conclusion, monotherapy with erlotinib in GBM relapses
patients with high protein expression for PTEN (???),
EGFR (???), and EGFRvlII (???) showed low toxicity
but minimal efficacy and the trial stopped.
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Introduction
Mutations affecting the epidermal growth factor receptor
(EGFR) expression or activity could result in cancer.
Attempting to improve patient survival, inhibition of the
EGFR pathway is an attractive therapeutic target [1–4]. EGFR
activation increases cell proliferation, migration, and inva-
siveness, and decreases apoptosis by downstream signaling,
especially via the RAS pathway [1–4]. Between 40 and 50 %
of glioblastoma multiforme (GBM) cases carry alterations of
the EGFR, and approximately half of these co-express the
mutated variant EGFRvIII, which has a deletion of exons 2–7
that generates a constitutively active receptor, even in the
absence of ligand binding [2]. Several small molecules and
antibodies directed against EGFR has been successfully used
as EGFR inhibitors and clinically tested. Erlotinib and gefitinib
belong to the group of small inhibitory molecules currently use
in mono or combined therapy in some cancer diseases models.
Advanced high-grade astrocytomas as GBM has a poor
outcome, with a very low survival rate. Temozolomide (TMZ)
an oral alkylating agent is the main therapy used for GBM
treatment, although only a partial improvement on progression
free survival and overall survival has been detected. Few trials
have been described to benefited from erlotinib or gefitinib [2,
3] and in these studies no clear correlation has been found
between drug response and EGFR expression. Mellinghoff
et al. [2], however, identified two molecular events in tumor
patients who could be related with a positive response to
erlotinib or gefitinib: the expression of EGFRvIII, and PTEN,
a tumor-suppressor protein that inhibits the phosphatidylino-
sitol 30 kinase signaling pathway downstream EGFR.
According with these authors, coexpression of EGFRvIII and
PTEN proteins, as detected by immunohistochemistry (IHC),
highly correlated with clinical responses to EGFR kinase
inhibitors. To test this hypothesis, we performed a phase II
study of erlotinib treatment in patients with relapsed GBM.
Materials and methods
Patients and treatment
All patients signed an informed consent form before enrol-
ment. All patients had recurrent GBM. The eligibility criteria
were age[18 years, life expectancy[8 weeks, and Kar-
nofsky performance status (KPS) C 60 with histological
confirmed disease. All patients were required to have pre-
treatment brain magnetic resonance images (MRI) within the
14 days before therapeutic treatment, and to have been
receiving a stable steroid dosage for C5 days. Because erl-
otinib is metabolized by the cytochrome P450 isoenzyme 3A4
(70 %) and CYP 1A2 (30 %), patients taking enzyme-
inducing anti-epileptic drugs (EIAEDs) were not eligible.
There were no limitations regarding prior relapses and prior
treatments. Normal bone marrow function, adequate liver
function (SGOT and bilirubin\1.5 times times the upper
limit of normality ULN), and adequate renal function (creat-
inine\1.5 mg/dL) within 14 days prior to registration, was
required for all patients. Women of childbearing potential and
their couples had to use adequate contraception throughout the
study period and for 12 weeks after its completion. The
response was evaluated using the McDonald criteria.
Exclusion criteria were: GBM previously treated with
anti EGFR drugs, any previous infiltrating neoplasia within
the last 5 years, severe cerebral hemorrhage following the
biopsy, anticonvulsant inducer/inhibitor treatment of the
CYP3A4 enzymes or treatment with other drugs that
interact with the metabolism of the study drug and that
could not be appropriately replaced with another drug
without possible interactions; pregnant or lactating women,
active cardiovascular disease, hypertension not controlled
by standard anti-hypertensive medications, unstable
angina, congestive heart disease (NYHA grade 3–4), car-
diac arrhythmia or prior myocardial infarction less than
1 year prior to inclusion. Erlotinib tablets were taken either
1 h before or 2 h after meals, in the morning. The dose was
150 mg/day on a continuous daily basis.
Patients with recurrent disease were treated at four-week
(one cycle) intervals. Treatment was continued indefinitely
as long as there were no unacceptable toxicities or tumor
progression. No other chemotherapy was during treatment
with erlotinib.
Pre-treatment and treatment evaluation
Within 14 days prior to treatment, medical history, physical
examination, brain MRI and hematology and biochemistry
blood analysis were required. A complete blood count with
differential and platelet counts and a comprehensive meta-
bolic panel were performed every 4 weeks during treatment.
A physical and neurological examination was performed
every 4 weeks, and brain imaging every 8 weeks. Clinical
response was evaluated according MacDonald Criteria.
Evaluations during the study
Toxicities were graded according to the National Cancer
Institute Common Terminology Criteria Version 3.0. Fol-
low-up of toxicity, neurological status, and KPS was
414 J Neurooncol (2014) 116:413–419
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performed monthly and MRI was performed every
8 weeks, until disease progression occurred.
Statistical methods
Overall response (OR) (defined using by Macdonald Cri-
teria) and progression-free survival at 6 months (PFS 6 m)
were considered primary endpoints. Secondary endpoints
were OS and toxicity. The planned sample size was 40 (all
GBM). A Simon two-stage design (response rate
P0 = 15 %, P1 = 35 %, a = 0.10, b = 0.10) required at
least two responses in the first 13 patients to expand to a
second cohort.
Response rate, PFS-6 (recurrent MG), and OS-12 were
based on the proportion of patients known to have achieved
that endpoint using, the intention to treat concept. Median
PFS and OS were calculated from the Kaplan–Meier
curves. Time was measured as from registration date. All
patients receiving per protocol treatment were included in
the safety assessment. The analysis of toxicity was reported
using the CTCAE v3.0.
Results
Between February 2008 and February 2010, 13 patients
from the Medical Oncology Department, Hospital Sant
Creu i Sant Pau, with relapse GBM met the inclusion cri-
teria and were recruited into the study. The Hospital
Clinical Trials Advisor Committee authorized the trial. All
patients gave their written informed consent. The baseline
characteristics of the patients are summarized in Table 1.
The correlation data between EGFRvIII and PTEN con-
sidering the IHC, FISH and RT-PCR results are described
in Table 2.
Treatment and dose intensity
Thirteen patients (6 men, 7 women) with recurrent GBM
received 150 mg erlotinib daily. Median age was 53 years,
median KPS was 80, and media number of patient prior
treatments for relapses was two.
Dose reduction for toxicity was not needed in any
patient. The main treatment-related toxicity was dermatitis,
grade 1 in 8 patients and grade 2 in 5 patients. No grade 3
toxicity was observed. The toxicities are summarized in
Table 3.
There was one partial response and three stable diseases
(one of them still stable at 18 months). PFS at 6 m was
20 %. Median progression free survival was 3.9 months
(IC 1.6–6.1). Median survival was 7 months (IC 1.41–4.7)
(Figs. 1, 2). Only one patient evidenced a good response.
Considering these poor results, we discarded the initial
hypothesis and the study was stopped because of ethical
reasons (Table 4).
Biomarker analysis
A weak significant linear trend association between EG-
FRvIII IHC staining (high, intermediate, or low) or nega-
tive, and EGFR FISH (positive vs. negative), p = 0.035
has been found. Nevertheless, no association was found
when comparing PTEN or EGFR IHC analysis versus
FISH analysis.
Discussion
The aim of the present phase II trial, was to investigate
whether the coexpression of EGFRvIII and PTEN proteins,
as detected by IHC, correlates with a positive clinical
outcome to erlotinib, a EGFR kinase inhibitor, as previ-
ously reported [2].
The response to EGFR inhibition in relapsed glioblas-
toma (GBM) has been widely studied in recent years but
results are non-conclusive. Different clinical trials have
been developed using EGFR inhibitors in monotherapy
regime or in combination with other drugs. Although, the
first trial using gefitinib give raise noresponse [1], two new
studies, offered encouraging results [2, 3].
Mellinghoff et al. [2] showed that coexpression of EG-
FRvIII and PTEN was associated with the response
observed when using EGFR kinase inhibitors, suggesting
that EGFRvIII and PTEN expression by IHC was sufficient
Table 1 Patient demographics and previous chemotherapies
Patient demographics (N = 14)
Males/females 7/6





Previous 1st line chemotherapy
Stupp protocol 13




Carmustine implant after 2nd surgery 2
Procarbazine?CCNU?Vincristine (PCV) 1
Previous 3rd line chemotherapy
Bevacizumab?CPT11 3
Extended temozolomide 2
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to select the patient responders cohort to EGFR inhibitors.
Survival obtained in these patients after the treatment with
EGFR inhibitors was 21.7 months in responders versus
5.8 months in non-responders (p = 0.01). The average
time to progression was 9.7 versus 1.7 months (p \ 0.001).
No mutations of EGFR gene were detected in seven
patients who responded. EGFRvIII was detected in 46 % of
patients. Six out of the 12 patients whose tumor expressed
EGFRvIII responded to EGFR inhibitors (p = 0.003).
None of the 13 patients whose tumors lacked PTEN
responded to treatment. The probability of response was
highest when the tumors coexpressed EGFRvIII and PTEN
(OR 51; 95 % IC 4–669; p \ 0.0001) [2].
An erlotinib therapeutic response on relapse GBM
patients has been previously reported [3]. In this trial a
partial responses was detected on 8 of 41 treated patients
with this agent, concluding that the patients with GBM
tumors who have high levels of EGFR expression and low
levels of phosphorylated PKB/Akt had better response to
erlotinib treatment than those with low levels of EGFR
expression and high levels of phosphorylated PKB/Akt [3].
However, EGFR inhibitors response on GBM is still
controversial. Despite those two studies with positive
results, most studies in patients with relapsed glioblastomas
treated with EGFR inhibitors obtained negative findings,
such as the EORT randomized phase II trial [5]. This study
included 110 patients, 54 treated with erlotinib and 56 with
TMZ or BCNU (bis-chloroethylnitrosourea), showing that
PFS at 6 months was 12 % for erlotinib and 24 % for the
control arm and an similar OS similar in both arms. In
contrast with the study of Mellingoff’s study, patients with
EGFRvIII mutations [13] in the erlotinib arm and eight in
the control arm) had shorter PFS and survival. Investigators
concluded that response to erlotinib was not correlated with
the expression of EGFR or EGFRvIII [5]. In our present
study patient overall survival was only 7 months, and
median progression-free survival was only of 3 months;
furthermore, only one patient evidenced a good response.
Considering these poor results, we stopped the study for
ethical reasons. Similarly, other trials using erlotinib in
first-relapse glioblastoma also stopped early on due to the
low response rate. In this trial described by Young et al [6]
median response, 6-month progression-free survival, and
median survival were similar to those described in our
study. EGFR amplification was never found associated
with erlotinib activity. Raizer et al. [7] found similar results
on 53 erlotinib treated patients with recurrent glioma with
median PFS in 2 months. They concluded that erlotinib
gives minimal response for recurrent GBM.
Given the poor results of EGFR inhibitors in mono-
therapy, several groups have developed combinatory
Table 3 Toxicities
Adverse event Incidence
N (14) Rate (%)
Dermatitis 8 57
Grade 1
Grade 2 5 35
Grade 3 0 0
Diarrhea
Grade 1 6 42
Grade 2 1 7
Fig. 1 Kaplan–Meier plots of progression free survival
Fig. 2 Kaplan–Meier plots of overall survival
Table 4 Types of Responses
Type of response N Rate (%)
Partial response 1 7
Stable disease 3 21
Progression disease 10 72
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therapy in an attempt to improve the outcomes. However,
results have been discouraging. So, a pilot study to assess
the tolerability and efficacy of everolimus with gefitinib in
patients with recurrent GBM founding a clinical benefit in
37 % of patients, with a PFS of 2.6 months [8].
Following new combo therapy trials, EGFR inhibitors
(erlotinib and/or gefitinib) were use in combination with
the inhibitor of mTOR inhibitor sirolimus. In one trial,
19 % of the 28 enrolled GBM patients experienced a par-
tial response and 50 % had stable disease, with a 6-month
PFS rate of 25 %. A surprisingly positive result was
obtained in an small cohort of patients [9]. Erlotinib was
also combined with carboplatin on treatment of recurrent
glioblastomas [10]. At this phase II study Groot et al. [10]
found an average time to progression of 15.2 weeks,
slightly better data than previously published, but using a
low number of heterogeneous selected patients. None of
the 32 recurrent glioblastoma patients achieved either
complete or partial responses when erlotinib was used in
combinatory therapy with sirolimus [11].
Furthermore, erlotinib was also used in combo therapy with
biological therapeutic compounds as bevacizumab in a phase
II study of recurrent malignant glioma tumors. Bevacizumab
(10 mg/kg) was given intravenously every 2 weeks. PFS-6
and median OS were 28 % and 42 weeks for GBM patients.
Most of the toxicities were mild. Unfortunately, erlotinib did
not seem to add any further clinical benefit compared to
patients who received bevacizumab alone.
Although the pharmacokinetics of erlotinib in both healthy
volunteers and adult patients with cancer has been well
characterized [12–14]. Very little is known about the central
nervous system penetration and exposure to this drug which is
a critical issue in the treatment of patients with primary brain
tumors [15]. Vivanco et al. [16] demonstrated that the disap-
pointing clinical activity of first-generation EGFR inhibitors
in GBM versus lung cancer might be attributed to the different
conformational requirements of mutant EGFR.
Regarding our study, one possible explanation for the
negative results could be related with the plethora of
genetic alterations found in the glioblastoma tumors [17].
Molecular analysis of these tumors identified gene EGFR
amplification and multiple types of EGFR mutations, the
most common being EGFR variant III (EGFRvIII), loss of
the tumor-suppressor protein PTEN, overexpression of
PDGFR (platelet-derived growth factor receptor) and a
mutation in gene TP53 [18].
Amplification of the EGFRvIII fragment by RT-PCR
was detected in 4/13 cases (30 %), similarly to recent
studies [19]. However, no correlation was found between
EGFRvIII IHC and RT-PCR analysis results. No differ-
ences in IHC scoring were detected between cases har-
boring an EGFRvIII RT-PCR positive result versus those
cases that did not shown the exons 2–7 deletion variants.
Since PTEN has been described as required for a
response to EGFR inhibitors [20], and previous studies
have shown no responses in patients whose tumors lack
PTEN [2], positive expression of PTEN by IHC was con-
sidered as inclusion criteria for this study. All samples from
the 13 patients were positive for PTEN by IHC. Surpris-
ingly, when measured by FISH, using specific probes,
PTEN gene copy number was altered, both by LOH or
monosomy in 8 out of 13 patents (61.5 %). FISH analysis
allows a reliable detection of the status of the gene but may
not be a definitive reflect of the status of the protein.
Moreover, the election of the antibody used for IHC ana-
lysis may also be determinant for PTEN protein status
analysis [21]. In our study, we used the PTEN 6H2.1 clone
(DAKO), as described in previous studies [2], on which
responders almost 50 % of PTEN positive patients [2].
Studies in larger cohorts with positive response results are
needed to elucidate the correct approach for PTEN status.
Moreover, a better probability of a clinical response to
EGFR kinase inhibitors was associated with coexpression
of EGFRvIII and PTEN [2]. In our study, a partial response
was shown in one out of the tree patients showing this
pattern of alterations.
We found a weak significant linear trend association
between EGFRvIII IHC results (being high, medium, low
or negative) and EGFR FISH (positive vs. negative,
p = 0.035). Previous studies have shown that there is an
association between the presence of EGFR gene amplifi-
cation and the EGFR genetic variant III in GBM and other
tumor types [22], being patients carrying both EGFR
amplification and EGFRvIII those with a worse survival. In
our studies, the four EGFRVIII positive patients did also
shown EGFR amplification, being a feasible reason for the
poor response obtained.
Since the published data correlating PTEN and EG-
FRvIII IHC status to EGFR inhibitor response in glio-
blastoma patients, there has not been one single study that
recapitulated this data. Consequently, our results support
that EGFRVIII and PTEN measurement by IHC is not a
solid approach for patient selection for anti-EGFR therapy,
being EGFR also a marker to be included in the selection.
Our results also concluded the relevance of FISH and PCR
as detection of PTEN and EGFR measurement in future
trials. In conclusion, we found that erlotinib provided
minimal beneficial activity on relapse GBM patients and
therefore, we consider that this drug is not cost-effective in
the treatment relapsed GMB patients who express EG-
FRVIII and PTEN as identified by IHC.
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